{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 33,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "The slide uses a feature-comparison matrix to highlight the competitive advantage of RL-007.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/13",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Publicly available information, including company websites and clinicaltrials.gov. Note: GABA = gamma-Aminobutyric acid; GlyT1 = Glycine transporter type-1; GPR139 = G Protein-Coupled Receptor 139; 5-HT2a = Serotonin 2A receptor; TAAR1 = Trace Amine-Associated Receptor 1. 1. RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "033189e8-7586-44c7-9fbe-bc3da757e020",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Comparison matrix of RL-007 vs competitors (Boehringer Ingelheim, Karuna, Takeda, Minerva, Sunovion) across compound, stage, MOA, and focus areas.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acefe3ca-5a76-4a39-bdf4-ab62f951ee9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "CIAS & Schizophrenia landscape: RL-007's unique pharmacology, acute cognitive benefit and excellent tolerability differentiate it from pipeline competitors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "936bc67d-d448-4980-89de-ce8736a1cdf6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "6e251981-5dd5-4a35-a2d8-0a4c888c9bcd",
      "evidence": "The slide uses a feature-comparison table to differentiate the product from competitors.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}